Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 13/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725856 | 0.80 | CA1 (0.51) | CA1CA2ACACBEPHX1 | |
| SCHEMBL13400240 | 0.80 | ALDH1A1 (0.43) | CA1CA2ACACBEPHX1 | |
| SCHEMBL13400275 | 0.79 | ACACB (0.41) | RORCCA1CA2ACACBEPHX1 | |
| SCHEMBL13400241 | 0.79 | CA1 (0.40) | RORCCA1CA2ACACBEPHX1 | |
| SCHEMBL3388472 | 0.77 | CA1 (0.41) | RORCCA1CA2CCR2ACACB | |
| SCHEMBL1710605 | 0.77 | CA1 (0.38) | CA1CA2ACACBEPHX1 | |
| SCHEMBL1724729 | 0.76 | DDB1 (0.48) | RORCCA1CA2ACACBEPHX1 | |
| SCHEMBL1498399 | 0.76 | RORC (0.50) | RORCCACNA1BCYP3A4CYP2C19CCR2 | |
| SCHEMBL1498398 | 0.76 | RORC (0.50) | RORCCACNA1BCYP3A4CYP2C19CCR2 | |
| SCHEMBL12692913 | 0.76 | RORC (0.50) | RORCCACNA1BCYP3A4CYP2C19CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344451-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010028088-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | RORC 987/4885CACNA1B 2464/4885CYP3A4 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.